PERIOPERATIVE ANTICOAGULATION MANAGEMENT: A HEMATOLOGIST–CARDIOLOGIST PERSPECTIVE ON RISK STRATIFICATION AND THERAPEUTIC DRUG MONITORING

Direct oral anticoagulants (DOACs) are widely used for thromboprophylaxis in atrial fibrillation and venous thromboembolism. Their marketing emphasizes predictable pharmacokinetics and no need for routine monitoring. However, the perioperative period exposes critical limitations of this paradigm, especially in high‑risk populations excluded from landmark trials. This narrative review integrates hematology and cardiology perspectives. We critically examined real‑world evidence on perioperative DOAC management, focusing on patients with extreme body weight, renal or hepatic impairment, active malignancy, thrombocytopenia, bariatric surgery, and drug–drug interactions. Guideline recommendations and commercial influences were analyzed. Routine therapeutic drug monitoring (TDM) is unnecessary for low‑risk elective procedures in standard patients. However, selective TDM is essential in high‑risk populations where DOAC pharmacokinetics are unpredictable. We identified specific indications for TDM (extreme body weight, CrCl<50 mL/min, Child‑Pugh B cirrhosis, bariatric surgery, interacting drugs) and provided practical algorithms for elective, urgent and emergency surgery. Low‑Molecular‑Weight heparin (LMWH) is preferred when DOAC pharmacokinetics are unpredictable, including malabsorption syndromes, severe thrombocytopenia, and advanced liver disease. Marketing influences have perpetuated the “no monitoring” dogma despite accumulating evidence of harm in vulnerable subgroups. A one‑size‑fits‑all approach to perioperative anticoagulation is unsafe in complex patients. Selective TDM improves safety in high‑risk scenarios. LMWH remains a preferred alternative when DOAC pharmacokinetics are unpredictable. Clinicians should recognise marketing influences and adopt evidence‑based, individualised strategies. Peer Review History: Received 25 July 2026; Reviewed 11 September 2026; Accepted 9 October; Available online 15 November 2026 Academic Editor: Dr. Essam Mohamed Eissa, Beni-Suef University, Egypt, [email protected] Reviewers: Dr. Taiwo O Elufioye, University of Ibadan, Nigeria, [email protected] Dr. Showkat Ahmad Bhawani, UNIMAS Sarawak, Malaysia, [email protected]

Authors

Publication Details

Journal
Universal Journal of Pharmaceutical Research
Published
2026-11-15
DOI
https://doi.org/10.22270/ujpr.v11i5.1673
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PERIOPERATIVE ANTICOAGULATION MANAGEMENT: A HEMATOLOGIST–CARDIOLOGIST PERSPECTIVE ON RISK STRATIFICATION AND THERAPEUTIC DRUG MONITORING

Olga Goryacheva, Emmanuel Ifeanyi Obeagu
Universal Journal of Pharmaceutical Research
Atrial Fibrillation Management and Outcomes
article

PERIOPERATIVE ANTICOAGULATION MANAGEMENT: A HEMATOLOGIST–CARDIOLOGIST PERSPECTIVE ON RISK STRATIFICATION AND THERAPEUTIC DRUG MONITORING

Olga Goryacheva, Emmanuel Ifeanyi Obeagu
article en

Abstract

Direct oral anticoagulants (DOACs) are widely used for thromboprophylaxis in atrial fibrillation and venous thromboembolism. Their marketing emphasizes predictable pharmacokinetics and no need for routine monitoring. However, the perioperative period exposes critical limitations of this paradigm, especially in high‑risk populations excluded from landmark trials. This narrative review integrates hematology and cardiology perspectives. We critically examined real‑world evidence on perioperative DOAC management, focusing on patients with extreme body weight, renal or hepatic impairment, active malignancy, thrombocytopenia, bariatric surgery, and drug–drug interactions. Guideline recommendations and commercial influences were analyzed. Routine therapeutic drug monitoring (TDM) is unnecessary for low‑risk elective procedures in standard patients. However, selective TDM is essential in high‑risk populations where DOAC pharmacokinetics are unpredictable. We identified specific indications for TDM (extreme body weight, CrCl<50 mL/min, Child‑Pugh B cirrhosis, bariatric surgery, interacting drugs) and provided practical algorithms for elective, urgent and emergency surgery. Low‑Molecular‑Weight heparin (LMWH) is preferred when DOAC pharmacokinetics are unpredictable, including malabsorption syndromes, severe thrombocytopenia, and advanced liver disease. Marketing influences have perpetuated the “no monitoring” dogma despite accumulating evidence of harm in vulnerable subgroups. A one‑size‑fits‑all approach to perioperative anticoagulation is unsafe in complex patients. Selective TDM improves safety in high‑risk scenarios. LMWH remains a preferred alternative when DOAC pharmacokinetics are unpredictable. Clinicians should recognise marketing influences and adopt evidence‑based, individualised strategies. Peer Review History: Received 25 July 2026; Reviewed 11 September 2026; Accepted 9 October; Available online 15 November 2026 Academic Editor: Dr. Essam Mohamed Eissa, Beni-Suef University, Egypt, [email protected] Reviewers: Dr. Taiwo O Elufioye, University of Ibadan, Nigeria, [email protected] Dr. Showkat Ahmad Bhawani, UNIMAS Sarawak, Malaysia, [email protected]

Universal Journal of Pharmaceutical Research
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon